|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1996-11-14
|
|
pubmed:abstractText |
The safety and immunogenicity of investigational conjugates, composed of the O-specific polysaccharides of Shigella sonnei and Shigella flexneri type 2a covalently bound to Pseudomonas aeruginosa recombinant exoprotein A (rEPA), were evaluated in 192 Israeli soldiers. None had significant local reactions or fever. Fourteen days after injection, 90% of S. sonnei-rEPA recipients and 73 to 77% of S. flexneri-rEPA recipients had a fourfold or greater increase in serum immunoglobulin G (IgG) and IgA anti-lipopolysaccharide (anti-LPS) levels; at 2 years, these remained higher than at prevaccination (P < 0.01). There was a fourfold or greater increase in IgM anti-LPS in 20% of vaccinees at 2 weeks, but levels returned to prevaccination values at 6 to 12 months. IgG was the highest and most sustained class of LPS antibodies. Reinjection at day 42 did not boost antibody levels. Eighteen of 23 (78%) who received S. sonnei-rEPA and 13 of 19 (68%) who received S. flexneri-rEPA. had significant IgA-secreting cell responses. Significant IgG antibody-secreting cell responses were detected in 19 of 23 (83%) and 11 of 19 (58%) volunteers following vaccination with S. sonnei-rEPA and S. flexneri 2a-rEPA, respectively. On the basis of these data, further evaluation of the Shigella conjugates for protective efficacy in field trials in Israel was started.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-1381621,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-1500527,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-1673210,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-1706731,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-1937803,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-2041956,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-2152154,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-2182727,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-2204243,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-2370107,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-2454893,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-2463995,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-2656880,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-3283258,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-3487597,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-3516876,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-3517189,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-3623987,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-3692749,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-5780532,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-6349988,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-7700752,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-8286636,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8926071-8359890
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0019-9567
|
|
pubmed:author |
pubmed-author:AshkenaziSS,
pubmed-author:ChuCC,
pubmed-author:CohenDD,
pubmed-author:GreenMM,
pubmed-author:LermanYY,
pubmed-author:OreCC,
pubmed-author:RobbinsJ BJB,
pubmed-author:RobinGG,
pubmed-author:SadoffJ CJC,
pubmed-author:SchneersonRR,
pubmed-author:ShiloachJJ,
pubmed-author:SleponRR,
pubmed-author:TaylorD NDN
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4074-7
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:8926071-Adolescent,
pubmed-meshheading:8926071-Adult,
pubmed-meshheading:8926071-Antibodies, Bacterial,
pubmed-meshheading:8926071-Bacterial Vaccines,
pubmed-meshheading:8926071-Humans,
pubmed-meshheading:8926071-Immunoglobulin A,
pubmed-meshheading:8926071-Immunoglobulin G,
pubmed-meshheading:8926071-Lipopolysaccharides,
pubmed-meshheading:8926071-Male,
pubmed-meshheading:8926071-Shigella,
pubmed-meshheading:8926071-Vaccines, Conjugate
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.
|
|
pubmed:affiliation |
Medical Corps, Israel Defence Force and Sackler School of Medicine, Tel Aviv University.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, Non-P.H.S.,
Randomized Controlled Trial
|
